Zentera Therapeutics, a Shanghai, China-based clinical-stage biopharmaceutical company, raised $75M in Series B funding.
The round was led by OrbiMed Advisors Asia and Tybourne Capital Management with participation from Avidity Partners, Casdin Capital, Surveyor Capital, Farallon Capital Management, Lilly Asia Ventures, Logos Capital, Perceptive Advisors, Redmile Group and Viking Global Investors.
The company intends to use the funds to advance the development of three Zentalis-discovered oncology clinical candidates as well as business development for future pipeline additions in China.
Formed by Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) to develop cancer therapies in China, Zentera Therapeutics is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics. Led by CEO Dr. Anthony Sun, who is also the Chairman and Chief Executive Officer at Zentalis, the company is developing a broad pipeline of oncology candidates, including Zentalis-discovered ZN-c3, a WEE1 inhibitor, ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, and ZN-d5, a BCL-2 inhibitor. Zentera has operations in both Shanghai and Beijing.
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers with operations in both New York and San Diego.